Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia

Arch Neurol. 2006 Oct;63(10):1479-82. doi: 10.1001/archneur.63.10.1479.

Abstract

Background: To our knowledge, there have been no reports on the control of central nervous system symptoms in patients with ataxia-telangiectasia.

Objective: To preliminarily determine the effectiveness of corticosteroid therapy on the central nervous system symptoms of a child with ataxia-telangiectasia in whom neurological signs improved when, occasionally, he was given betamethasone to treat asthmatic bronchitis attacks.

Design: Case report.

Setting: Tertiary care hospital. Patient A 3-year-old boy with the classic hallmarks and a proved molecular diagnosis of ataxia-telangiectasia.

Interventions: We used betamethasone, 0.1 mg/kg per 24 hours, divided every 12 hours, for 4 weeks to preliminarily determine its effectiveness on the child's central nervous system symptoms and its safety. Methylprednisolone, 2 mg/kg per 24 hours, divided every 12 hours, was then given in an attempt to perform a long-term treatment.

Results: There were improvements in the child's neurological symptoms 2 or 3 days after the beginning of the drug treatment. After 2 weeks of treatment, the improvement was dramatic: the disturbance of stance and gait was clearly reduced, and the control of the head and neck had increased, as had control of skilled movements. At 4 weeks of treatment, adverse effects mainly included increased appetite and body weight and moon face. No beneficial effect was obtained when, after 4 weeks, betamethasone was replaced with methylprednisolone. Six months later, without therapy, the child continued to experience severe signs of central nervous system impairment.

Conclusion: Controlled studies to better understand the most appropriate drug and therapeutic schedule are required.

Publication types

  • Case Reports

MeSH terms

  • Ataxia / drug therapy
  • Ataxia / etiology
  • Ataxia / physiopathology
  • Ataxia Telangiectasia / diagnosis
  • Ataxia Telangiectasia / drug therapy*
  • Ataxia Telangiectasia / physiopathology
  • Ataxia Telangiectasia Mutated Proteins
  • Betamethasone / administration & dosage*
  • Cell Cycle Proteins / genetics
  • Cell Cycle Proteins / metabolism
  • Cerebellum / drug effects
  • Cerebellum / physiopathology
  • Child, Preschool
  • Conjunctiva / drug effects
  • Conjunctiva / pathology
  • Conjunctiva / physiopathology
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Gait Disorders, Neurologic / drug therapy
  • Gait Disorders, Neurologic / etiology
  • Gait Disorders, Neurologic / physiopathology
  • Glucocorticoids / administration & dosage*
  • Humans
  • Male
  • Methylprednisolone / administration & dosage
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / metabolism
  • Recovery of Function / drug effects
  • Recovery of Function / physiology
  • Treatment Outcome
  • Tumor Suppressor Proteins / genetics
  • Tumor Suppressor Proteins / metabolism

Substances

  • Cell Cycle Proteins
  • DNA-Binding Proteins
  • Glucocorticoids
  • Tumor Suppressor Proteins
  • Betamethasone
  • ATM protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • Protein Serine-Threonine Kinases
  • Methylprednisolone